• 543 Citations
  • 9 h-Index
20092019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Lorenza Alessia Di Guardo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

Melanoma Medicine & Life Sciences
Immunotherapy Medicine & Life Sciences
Safety Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Radiotherapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2009 2019

  • 543 Citations
  • 9 h-Index
  • 25 Article
  • 2 Review article
2 Citations (Scopus)

Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis

Galli, G., Cavalieri, S., Di Guardo, L., Cimminiello, C., Nichetti, F., Corti, F., Garcia, M. A., Pappalardi, B., Fallai, C., De Braud, F., Platania, M. & Del Vecchio, M., Apr 1 2019, In : Oncology Research and Treatment. 42, 4, p. 182-188 7 p.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Radiotherapy
Brain
Survival

Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Jan 1 2019, (Accepted/In press) In : Tumori.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Lymphocyte Count
L-Lactate Dehydrogenase
Survival
7 Citations (Scopus)

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

Indini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F. & Del Vecchio, M., Feb 13 2019, In : Journal of Cancer Research and Clinical Oncology. 145, 2, p. 511-521 11 p.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Survival
Vitiligo
Programmed Cell Death 1 Receptor
Open Access
Immunotherapy
Melanoma
CTLA-4 Antigen
Cell Death
Vulva

Pembrolizumab in the treatment of advanced/metastatic melanoma: A single-center institution experience

Cimminiello, C., Indini, A., Di Guardo, L., Prisciandaro, M., Randon, G., Tolomio, E., De Braud, F. & Del Vecchio, M., Jun 1 2019, In : Melanoma Research. 29, 3, p. 289-294 6 p.

Research output: Contribution to journalArticle

Melanoma
Confidence Intervals
Therapeutics
Proportional Hazards Models
Disease-Free Survival